Comparative Evaluation of Topical Mitomycin‑C versus Interferon‑α2b in the Management of Ocular Surface Squamous Neoplasia (OSSN)
This prospective randomized study of 82 patients with primary ocular surface squamous neoplasia found that while topical mitomycin-C achieved faster lesion resolution than interferon-α2b, both treatments demonstrated comparable efficacy in complete response rates and no statistically significant differences in safety or the need for surgical intervention.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The surface of the eye is a delicate, living window that must remain clear and smooth for us to see the world. When this surface develops abnormal, potentially cancerous growths known as ocular surface squamous neoplasia, the condition threatens both vision and the structural integrity of the eye itself. For decades, the standard way to remove these growths was surgery, a precise but invasive procedure that could leave behind scars or damage the eye's ability to heal. In recent years, doctors have turned to liquid medicines applied directly to the eye as a gentler alternative. Two of the most common liquid treatments are a drug that stops cells from copying their DNA and a biological protein that helps the body's immune system recognize and clear away the abnormal tissue. While both have shown promise, doctors have lacked a clear, head-to-head comparison to know which one works better, which one acts faster, and which one is safer for the patient's eye.
A team of researchers at the Dr KNS Institute of Medical Sciences set out to answer these questions by conducting a careful, forward-looking study involving eighty-two patients. Each patient had a primary case of the eye condition and was randomly assigned to receive one of the two liquid treatments. One group received drops containing the biological protein, applied four times a day for up to three months. The other group received drops containing the cell-stopping drug, applied in a cycle of one week on and one week off for about six to eight weeks. The researchers watched closely over the next eighteen months, measuring how quickly the growths disappeared, whether the eyes remained healthy, and if any patients eventually needed surgery despite the treatment.
The results showed that both medicines are highly effective at clearing the disease. In the group treated with the biological protein, nearly ninety-three percent of the eyes saw the growths vanish completely. In the group treated with the cell-stopping drug, about eighty-three percent of the eyes achieved the same result. While the protein group had a slightly higher success rate, the difference was small enough that the researchers could not say with certainty that one medicine was truly superior to the other in terms of simply curing the condition. Both treatments successfully eliminated the visible signs of the disease in the vast majority of patients, proving that liquid therapy is a powerful tool for managing this eye problem without immediate surgery.
However, the two medicines behaved very differently regarding speed and side effects. The cell-stopping drug worked much faster, clearing the growths in a median time of one and a half months. The biological protein took longer, requiring a median of three and a half months to achieve the same clear result. This difference in speed is significant for patients who need a quick resolution. On the other hand, the biological protein was gentler on the eye. Only two patients in that group experienced any treatment-related side effects, such as mild irritation. In contrast, eight patients in the cell-stopping group reported side effects, including redness, irritation, and damage to the surface cells of the eye. Because of these side effects, more patients in the cell-stopping group eventually required surgical intervention to finish the job, though the difference in surgery rates was not statistically large enough to declare one treatment definitively safer than the other.
The study concludes that neither medicine is a clear winner for every situation. Instead, the choice depends on what the patient and doctor prioritize. If the goal is to remove the growth as quickly as possible and the eye is generally healthy, the faster-acting cell-stopping drug is a strong option. If the priority is to minimize irritation and protect the delicate surface of the eye, especially in patients who already have sensitive eyes, the biological protein is the better choice, even if it takes longer to work. The researchers emphasize that these treatments are not mutually exclusive with surgery but rather part of a larger toolkit. By offering two effective, non-surgical options with different strengths, doctors can now tailor their approach to the specific needs of each patient, balancing the desire for speed against the need for comfort and safety.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.